title: BETs abet Tam-R in ER-positive breast cancer.
abstract: Epigenetic modifications such as histone acetylation play a central role in the transcriptional regulation of many oncogenic drivers. Accumulating evidence suggests that pharmacological modulation of certain key epigenetic reader proteins such as BRD2/3/4 may serve as an attractive strategy for treatment of many cancers, including tamoxifen-resistant breast cancer.
authors.affiliation: 1] Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [2] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
authors.forename: Prasanna G
authors.initials: PG
authors.lastname: Alluri
authors.affiliation: 1] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [2] Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
authors.forename: Irfan A
authors.initials: IA
authors.lastname: Asangani
authors.affiliation: 1] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [2] Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA [3] Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [4] Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA [5] Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
authors.forename: Arul M
authors.initials: AM
authors.lastname: Chinnaiyan
mesh_terms: D000107:Acetylation; D001381:Azepines / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D018797:Cell Cycle Proteins; D019008:Drug Resistance, Neoplasm; D044127:Epigenesis, Genetic; D005260:Female; D011495:Histone-Lysine N-Methyltransferase / Q000378:metabolism; D006657:Histones / Q000378:metabolism; D006801:Humans; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D016601:RNA-Binding Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism*; D012097:Repressor Proteins / Q000378:metabolism; D013629:Tamoxifen / Q000627:therapeutic use; D014157:Transcription Factors / Q000037:antagonists & inhibitors / Q000378:metabolism; D014230:Triazoles / Q000627:therapeutic use; D000092468:Bromodomain Containing Proteins
chemical_list: D001381:Azepines; D001569:Benzodiazepines; D018797:Cell Cycle Proteins; D011495:Histone-Lysine N-Methyltransferase; D006657:Histones; D009687:Nuclear Proteins; D017346:Protein Serine-Threonine Kinases; D016601:RNA-Binding Proteins; D011960:Receptors, Estrogen; D012097:Repressor Proteins; D013629:Tamoxifen; D014157:Transcription Factors; D014230:Triazoles; C561695:(+)-JQ1 compound; C098415:BRD2 protein, human; D000092468:Bromodomain Containing Proteins; C109106:BRD3 protein, human; C441289:BRD4 protein, human; C554645:molibresib; C419586:NSD2 protein, human